



## **Kura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting**

June 7, 2017

LA JOLLA, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that preliminary data from the ongoing Phase 2 clinical trial evaluating the efficacy, safety and biomarkers of tipifarnib in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) were selected for a poster presentation at the 14th International Conference on Malignant Lymphoma (ICML) being held June 14-17, 2017 in Lugano, Switzerland. In addition, Kura's preliminary Phase 2 data in PTCL were also selected for a poster presentation at the 22nd Congress of the European Hematology Association (EHA) taking place June 22-25, 2017 in Madrid, Spain.

### **Details for the Poster Presentation at ICML**

**Title:** Preliminary Results from an Open-label, Phase II Study of Tipifarnib in Relapsed or Refractory T-cell Lymphoma

**Presenter:** Thomas E. Witzig, M.D., Mayo Clinic

**Abstract Number:** 255

**Date and Time:** Wednesday, June 14, 2017, poster may be viewed from Wednesday, June 14, 2017 at 12:00 CET through Friday, June 16, 2017 at 18:30 CET

**Location:** Marquee Parco Ciani

### **Details for the Poster Presentations at EHA**

**Title:** Preliminary Results from an Open-label, Phase II Study of Tipifarnib in Relapsed or Refractory T-cell Lymphoma

**Presenter:** Thomas E. Witzig, M.D., Mayo Clinic

**Abstract Number:** P571

**Poster Session:** EHA 22

**Date / Time:** Saturday, June 24, 2017, 7:30 – 19:00 CET

**Location:** IFEMA, Poster Area, Hall 7

In addition, data from a preclinical study of tipifarnib in T-cell leukemia by Dr. Mondejar (IDIVAL, Santander, Spain) showing cell line sensitivity to common T leukemia mutations will be presented at EHA as an E-poster.

**Title:** [T-Cell](#) Leukemia Sensitivity to Farnesyl Transferase Inhibition Using Tipifarnib

**Abstract Number:** E834

**Date / Time:** Friday, June 23, 09:30 CET through Saturday, June 24, 19:30 CET

**Location:** Poster Area, E-poster screens

### **About Kura Oncology**

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura's pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company's website at [www.kuraoncology.com](http://www.kuraoncology.com).

### **CONTACT INFORMATION**

#### **INVESTOR CONTACT:**

Robert H. Uhl

Managing Director

Westwicke Partners, LLC

(858) 356-5932

[robert.uhl@westwicke.com](mailto:robert.uhl@westwicke.com)

#### **CORPORATE COMMUNICATIONS CONTACT:**

Mark Corbae

Vice President

Canale Communications

(619) 849-5375

[mark@canalecomm.com](mailto:mark@canalecomm.com)



Kura Oncology, Inc.